Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) Equity Average (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Equity Average for 3 consecutive years, with $52.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 73.51% to $52.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $52.7 million, a 73.51% decrease, with the full-year FY2024 number at $88.5 million, changed N/A from a year prior.
  • Equity Average was $52.7 million for Q3 2025 at Inhibrx Biosciences, down from $81.5 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $198.9 million in Q3 2024 to a low of $27.5 million in Q1 2024.
  • A 3-year average of $98.3 million and a median of $86.5 million in 2023 define the central range for Equity Average.
  • Biggest YoY gain for Equity Average was 314.06% in 2025; the steepest drop was 73.51% in 2025.
  • Inhibrx Biosciences' Equity Average stood at $86.5 million in 2023, then soared by 80.27% to $156.0 million in 2024, then crashed by 66.23% to $52.7 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Equity Average are $52.7 million (Q3 2025), $81.5 million (Q2 2025), and $114.0 million (Q1 2025).